Kelix Bio Malta

Kelix Bio Malta company information, Employees & Contact Information

Explore related pages

Related company profiles:

KELIX bio is a buy-and-build specialty generic business focused on emerging markets and designed to compete through innovation and cost leadership. KELIX bio brings high-quality specialty products at affordable prices to populations across emerging markets who could not historically afford them. The company’s investors currently include Development Partners International (DPI), CDC Group, the UK’s publicly owned impact investor, and the European Bank for Reconstruction and Development (EBRD). KELIX bio takes guidance and inspiration from its core values of integrity, performance, quality, and care, to help it create value for all stakeholders, patients, healthcare professionals, payors, and ultimately its shareholders. KELIX bio serves a diverse base of clients, reaching out to governments through its participation in tenders, as well as hospitals, and partnering closely with healthcare professionals and caregivers. It differentiates itself from competitors through the uncompromising quality of its products and through its cost leadership. KELIX bio takes pride in materially expanding the pool of cancer patients that can now have access to oncology drugs at affordable prices.

Company Details

Employees
75
Founded
-
Address
Hhf014, Hal Far Industrial Estate,malta
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Malta
Looking for a particular Kelix Bio Malta employee's phone or email?

Kelix Bio Malta Questions

News

Mubadala’s KELIX bio acquires DiabTec LLC - ZAWYA

Mubadala’s KELIX bio acquires DiabTec LLC ZAWYA

Kelix bio makes fifth strategic deal since acquisition by Mubadala - VCCircle

Kelix bio makes fifth strategic deal since acquisition by Mubadala VCCircle

BII, DPI and EBRD announce exit from KELIX bio, a leading emerging markets biopharmaceutical platform they created in 2020 - British International Investment

BII, DPI and EBRD announce exit from KELIX bio, a leading emerging markets biopharmaceutical platform they created in 2020 British International Investment

KELIX bio Enters Into a Binding Commitment to Acquire PHI, a Leading Pharmaceutical Manufacturer in Morocco - Business Wire

KELIX bio Enters Into a Binding Commitment to Acquire PHI, a Leading Pharmaceutical Manufacturer in Morocco Business Wire

Mubadala Investment Company Acquires 100% of KELIX Bio in Full Ownership Deal - Private Equity Insights

Mubadala Investment Company Acquires 100% of KELIX Bio in Full Ownership Deal Private Equity Insights

Abu Dhabi’s Mubadala expands life sciences portfolio with acquisition of Kelix Bio - Economy Middle East

Abu Dhabi’s Mubadala expands life sciences portfolio with acquisition of Kelix Bio Economy Middle East

Mubadala acquires specialised pharmaceutical company KELIX bio - مكتب أبوظبي الإعلامي

Mubadala acquires specialised pharmaceutical company KELIX bio مكتب أبوظبي الإعلامي

Mubadala’s Kelix bio acquires GHH’s pharma assets to expand its life sciences portfolio - thenationalnews.com

Mubadala’s Kelix bio acquires GHH’s pharma assets to expand its life sciences portfolio thenationalnews.com

Mubadala’s KELIX bio buys four GlobalOne Healthcare pharma assets - Gulf Business

Mubadala’s KELIX bio buys four GlobalOne Healthcare pharma assets Gulf Business

Mubadala’s KELIX bio acquires four GlobalOne Healthcare Holding Pharma Assets to strengthen life sciences presence in the UAE - ZAWYA

Mubadala’s KELIX bio acquires four GlobalOne Healthcare Holding Pharma Assets to strengthen life sciences presence in the UAE ZAWYA

KELIX bio, pan-African biopharmaceutical platform signs agreement to acquire Morocco-based Pharmaceutical Institute - British International Investment

KELIX bio, pan-African biopharmaceutical platform signs agreement to acquire Morocco-based Pharmaceutical Institute British International Investment

Mubadala’s KELIX bio acquires Julphar’s DiabTec - Gulf Business

Mubadala’s KELIX bio acquires Julphar’s DiabTec Gulf Business

Mubadala to acquire Kelix bio in push to expand life sciences portfolio - thenationalnews.com

Mubadala to acquire Kelix bio in push to expand life sciences portfolio thenationalnews.com

Top Kelix Bio Malta Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant